{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:16:19Z","timestamp":1791393379619,"version":"4.3.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","award":["2024SF-YBXM-148"],"award-info":[{"award-number":["2024SF-YBXM-148"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bethune Charity Foundation","award":["BCF-IBW-XY-20231023-08"],"award-info":[{"award-number":["BCF-IBW-XY-20231023-08"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biotechnol"],"DOI":"10.1186\/s12896-025-01024-x","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:15:50Z","timestamp":1756275350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A novel feeder cell based on 4-1BBL and membrane-bound IL-21\/IL-15 induce highly expansion and anti-tumor effect of natural killer cells"],"prefix":"10.1186","volume":"25","author":[{"given":"Sha","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Wald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"issue":"3","key":"1024_CR1","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial.[J]. Nat Med. 2024;30(3):772\u201384.","journal-title":"Nat Med"},{"key":"1024_CR2","doi-asserted-by":"crossref","unstructured":"Lei W, Liu H, Deng W, et al. Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial[J]. Nat Cancer; 2025.","DOI":"10.1038\/s43018-025-00940-3"},{"issue":"4","key":"1024_CR3","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cell.2020.01.022","volume":"180","author":"P Dogra","year":"2020","unstructured":"Dogra P, Rancan C, Ma W, et al. Tissue determinants of human NK cell development, function, and Residence[J]. Cell. 2020;180(4):749\u2013e76313.","journal-title":"Cell"},{"issue":"8000","key":"1024_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier E, Rebuffet L, Narni-Mancinelli E, et al. Natural killer cell therapies[J]. Nature. 2024;626(8000):727\u201336.","journal-title":"Nature"},{"issue":"3","key":"1024_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy[J]. Nat Rev Drug Discov. 2020;19(3):200\u201318.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1024_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s40425-019-0652-7","volume":"7","author":"YH Choi","year":"2019","unstructured":"Choi YH, Lim EJ, Kim SW, et al. IL-27 enhances IL-15\/IL-18-mediated activation of human natural killer cells[J]. J Immunother Cancer. 2019;7(1):168.","journal-title":"J Immunother Cancer"},{"key":"1024_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3389\/fimmu.2017.00676","volume":"8","author":"J Wagner","year":"2017","unstructured":"Wagner J, Pfannenstiel V, Waldmann A, et al. A Two-Phase expansion protocol combining Interleukin (IL)-15 and IL-21 improves natural killer cell proliferation and cytotoxicity against Rhabdomyosarcoma[J]. Front Immunol. 2017;8:676.","journal-title":"Front Immunol"},{"key":"1024_CR8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3389\/fimmu.2017.00458","volume":"8","author":"M Granzin","year":"2017","unstructured":"Granzin M, Wagner J, K\u00f6hl U, et al. Shaping of natural killer cell antitumor activity by ex vivo Cultivation.[J]. Front Immunol. 2017;8:458.","journal-title":"Front Immunol"},{"issue":"1","key":"1024_CR9","doi-asserted-by":"publisher","first-page":"14916","DOI":"10.1038\/s41598-019-51287-6","volume":"9","author":"EO Ojo","year":"2019","unstructured":"Ojo EO, Sharma AA, Liu R, et al. Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells[J]. Sci Rep. 2019;9(1):14916.","journal-title":"Sci Rep"},{"issue":"1","key":"1024_CR10","doi-asserted-by":"publisher","first-page":"e30264","DOI":"10.1371\/journal.pone.0030264","volume":"7","author":"CJ Denman","year":"2012","unstructured":"Denman CJ, Senyukov VV, Somanchi SS, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells[J]. PLoS ONE. 2012;7(1):e30264.","journal-title":"PLoS ONE"},{"issue":"3","key":"1024_CR11","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00262-021-02982-9","volume":"71","author":"JL Thangaraj","year":"2022","unstructured":"Thangaraj JL, Phan MTT, Kweon S, et al. Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21[J]. Cancer Immunol Immunother. 2022;71(3):613\u201325.","journal-title":"Cancer Immunol Immunother"},{"key":"1024_CR12","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3389\/fimmu.2019.00879","volume":"10","author":"S Kweon","year":"2019","unstructured":"Kweon S, Phan MTT, Chun S, et al. Expansion of human NK cells using K562 cells expressing OX40 ligand and short exposure to IL-21.[J]. Front Immunol. 2019;10:879.","journal-title":"Front Immunol"},{"key":"1024_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-1-4939-3684-7_15","volume":"1441","author":"SS Somanchi","year":"2016","unstructured":"Somanchi SS, Lee DA. Ex vivo expansion of human NK cells using K562 engineered to express membrane bound IL21[J]. Methods Mol Biol. 2016;1441:175\u201393.","journal-title":"Methods Mol Biol"},{"issue":"7","key":"1024_CR14","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood-2014-02-556837","volume":"124","author":"M Imamura","year":"2014","unstructured":"Imamura M, Shook D, Kamiya T, et al. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15[J]. Blood. 2014;124(7):1081\u20138.","journal-title":"Blood"},{"issue":"1","key":"1024_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3892\/ijo.2015.3005","volume":"47","author":"X Li","year":"2015","unstructured":"Li X, He C, Liu C, et al. Expansion of NK cells from PBMCs using immobilized 4-1BBL and interleukin-21.[J]. Int J Oncol. 2015;47(1):335\u201342.","journal-title":"Int J Oncol"},{"key":"1024_CR16","doi-asserted-by":"crossref","unstructured":"Caignard A. NKG2D\/NKG2-Ligand pathway offers new opportunities in cancer treatment[J]. Front Immunol, 2019, 10.","DOI":"10.3389\/fimmu.2019.00661"},{"key":"1024_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2024.02.001","volume":"76","author":"Z Liu","year":"2024","unstructured":"Liu Z, Wang H, Liu H, et al. Targeting NKG2D\/NKG2DL axis in multiple myeloma therapy[J]. Cytokine Growth Factor Rev. 2024;76:1\u201311.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"Supplement 1","key":"1024_CR18","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1182\/blood-2022-169758","volume":"140","author":"N Albinger","year":"2022","unstructured":"Albinger N, Bexte T, Buchinger L, et al. CRISPR\/Cas9 gene editing of immune checkpoint receptor NKG2A improves the efficacy of primary CD33-CAR-NK cells against AML[J]. Blood. 2022;140(Supplement 1):4558\u20139.","journal-title":"Blood"},{"key":"1024_CR19","doi-asserted-by":"crossref","unstructured":"Qin Y, Cui Q, Sun G et al. Developing enhanced immunotherapy using NKG2A knockout human pluripotent stem cell-derived NK cells[J]. Cell Rep, 2024, 43(11).","DOI":"10.1016\/j.celrep.2024.114867"},{"issue":"1","key":"1024_CR20","doi-asserted-by":"publisher","first-page":"10555","DOI":"10.1038\/s41598-023-37779-6","volume":"13","author":"M Kaulfuss","year":"2023","unstructured":"Kaulfuss M, Mietz J, Fabri A, et al. The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells.[J]. Sci Rep. 2023;13(1):10555.","journal-title":"Sci Rep"},{"issue":"7","key":"1024_CR21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jcyt.2020.02.004","volume":"22","author":"S Michen","year":"2020","unstructured":"Michen S, Frosch J, F\u00fcssel M, et al. Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94\/NKG2A for expansion of functional primary natural killer cells with tolerance to self[J]. Cytotherapy. 2020;22(7):354\u201368.","journal-title":"Cytotherapy"}],"container-title":["BMC Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-025-01024-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12896-025-01024-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-025-01024-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T18:33:20Z","timestamp":1757442800000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbiotechnol.biomedcentral.com\/articles\/10.1186\/s12896-025-01024-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1024"],"URL":"https:\/\/doi.org\/10.1186\/s12896-025-01024-x","relation":{},"ISSN":["1472-6750"],"issn-type":[{"value":"1472-6750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experiment was approved by the Ethics Committee of The First Affiliated Hospital of Xi\u2019an Jiaotong University in Xi\u2019an, China (Approval no. XJTUAE2023-1883).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}